BET-inhibitors appear to be a welcome contribution for targeting the stem cell fraction in these neoplasms since it was shown earlier that brain tumor initiating cells express high levels of c-myc [17] and are therefore dependent on this transcription factor. The gene discussed is MYC; the disease is neoplasm.